Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Low
UBS
David Low
UBS
Wall Street Analyst
★★★☆☆
#1571
on 13Foresight · ranked by our own returns
33%
Success Rate
-9.9%
Average Return
1 of 3 calls profitable · +16.5% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 33% of David Low's ratings turned a profit when each position was held for 1 year — averaging -9.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

20 Buy 25 Hold 4 Sell
David's Stock Coverage 17 ratings · 2026-07-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
AU:REG
Regis Healthcare Ltd.
 Jul 08, 2026 HOLD Buy
-5.0% avg upside
6 analysts
$7.00
10.82% Upside
 ·
AU:ANN
Ansell
 Jul 06, 2026 HOLD Hold
+5.9% avg upside
9 analysts
$34.25
9.57% Upside
 ·
AU:CSL
CSL
 Jul 01, 2026 BUY Strong Buy
+46.1% avg upside
15 analysts
$158.00
28.52% Upside
 ·
AU:SHL
Sonic Healthcare Limited
 Jul 01, 2026 HOLD Buy
+21.1% avg upside
12 analysts
$19.60
7.63% Downside
 ·
AU:COH
Cochlear
Jul 01, 2026 HOLD Hold
+45.3% avg upside
15 analysts
$106.00
12.93% Downside
 ·
AU:RHC
Ramsay Health Care
 May 28, 2026 HOLD Hold
-4.0% avg upside
14 analysts
$42.90
2.30% Upside
 ·
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
 Apr 28, 2026 BUY Strong Buy
+39.5% avg upside
11 analysts
 — ·
AU:TLX
Telix Pharmaceuticals
 Aug 31, 2025 HOLD Strong Buy
+56.0% avg upside
13 analysts
$16.50
1.36% Upside
 ·
AU:IDX
Integral Diagnostics Ltd.
 Aug 27, 2025 BUY Buy
+52.7% avg upside
12 analysts
$3.40
65.06% Upside
 ·
AU:PNV
Polynovo
Aug 27, 2025 HOLD Strong Buy
+79.1% avg upside
5 analysts
$1.30
28.07% Upside
 ·
AU:NAN
Nanosonics Limited
 Aug 27, 2025 SELL Hold
+45.8% avg upside
7 analysts
$3.90
20.46% Upside
 ·
AU:HLS
Healius Limited
 Aug 25, 2025 SELL Strong Sell
+120.5% avg upside
10 analysts
$0.62
60.99% Upside
 ·
AU:PME
Pro Medicus Limited
 Aug 14, 2025 HOLD Strong Buy
+30.1% avg upside
9 analysts
$300.00
52.16% Upside
 ·
RMD
Resmed
 Aug 01, 2025 BUY Buy
+15.1% avg upside
27 analysts
$310.00
52.06% Upside
 -25.6%
AU:M7T
Mach7 Technologies
 Mar 02, 2025 BUY Strong Buy
+250.3% avg upside
5 analysts
$0.78
151.60% Upside
 ·
SKHHY
Sonic Healthcare
 Aug 23, 2021 HOLD Buy
5 analysts
 — -21.3%
CSLLY
CSL
 Dec 04, 2019 HOLD Buy
+981.6% avg upside
3 analysts
 — +17.2%
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Low — Frequently Asked Questions
How accurate are David Low's stock ratings?
Based on the calls 13Foresight could measure, about 33% of David's ratings were profitable over a one-year hold, with an average return of -9.9% per rating, or -22.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is David ranked on 13Foresight?
David Low is currently ranked #1571 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on AU:REG, AU:ANN, AU:CSL, AU:SHL, AU:COH, AU:RHC, AU:RMD, AU:TLX, AU:IDX, AU:PNV, AU:NAN, AU:HLS and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.